- Home
- GBIO vs PZC Comparison
GBIO vs PZC Comparison
Compare GBIO & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- PZC
- Stock Information
- Founded
- GBIO 2016
- PZC 2002
- Country
- GBIO United States
- PZC United States
- Employees
- GBIO N/A
- PZC N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- PZC Investment Managers
- Sector
- GBIO Health Care
- PZC Finance
- Exchange
- GBIO Nasdaq
- PZC Nasdaq
- Market Cap
- GBIO 29.2M
- PZC N/A
- IPO Year
- GBIO 2020
- PZC N/A
- Fundamental
- Price
- GBIO $0.32
- PZC $6.23
- Analyst Decision
- GBIO Strong Buy
- PZC
- Analyst Count
- GBIO 4
- PZC 0
- Target Price
- GBIO $7.33
- PZC N/A
- AVG Volume (30 Days)
- GBIO 1.1M
- PZC 48.2K
- Earning Date
- GBIO 08-06-2025
- PZC 01-01-0001
- Dividend Yield
- GBIO N/A
- PZC 4.68%
- EPS Growth
- GBIO N/A
- PZC N/A
- EPS
- GBIO N/A
- PZC N/A
- Revenue
- GBIO $24,556,000.00
- PZC N/A
- Revenue This Year
- GBIO N/A
- PZC N/A
- Revenue Next Year
- GBIO N/A
- PZC N/A
- P/E Ratio
- GBIO N/A
- PZC N/A
- Revenue Growth
- GBIO 146.47
- PZC N/A
- 52 Week Low
- GBIO $0.30
- PZC $6.30
- 52 Week High
- GBIO $3.65
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- GBIO 43.92
- PZC 47.52
- Support Level
- GBIO $0.35
- PZC $6.13
- Resistance Level
- GBIO $0.38
- PZC $6.19
- Average True Range (ATR)
- GBIO 0.03
- PZC 0.04
- MACD
- GBIO -0.00
- PZC 0.01
- Stochastic Oscillator
- GBIO 3.33
- PZC 88.89
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.